CD8A and cancer: LL-37 treatment appeared to reduce the immunosuppressive cells of MDSCs (CD11b+Gr-1+) and M2 macrophages (CD206+F4/80+) and to increase the anti-cancer effectors CD4+T (CD4+CD3+) and CD8+T (CD8+CD3+) cells (Figure 6A).